[ Inside the business ]

JNJ stock analysis

JNJ · Johnson & Johnson

Pharmaceutical preparations. Growing 6%.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 3.5× sales in 5 yrs. Evidence: sales +6% · 29¢ profit/$1 · In-body cell therapy rising.

01 What's priced in?3.5× sales in 5 yrs
Sales now$74.3B
Needed in 5 yrs$262.6B
02 Is the wave rising?In-body cell therapy · 2.8×
'20'21'22'23'24'2514
#9 of 20 mentioning it
03 Will customers keep buying?Sales +6%, steady
No customer over 10%
Sales +6%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 29¢ per $1, rising
'11'12'12'1329¢
Before running costs: 69% → 68%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −2.6%/yrDebt $44.7B
07 What could break it?3 to watch
  • Growth slowing
  • Insiders sold $74M outside pre-set plans
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth slowing.

Sales growth +10%, +7%, then +6% vs. a year ago.

What could go wrong

Steadier than most.

It has moved 0.5× the market. In the 2008 crisis it fell 20% while the market fell 51%. Debt is moderate.

Speculative check

Not classified.

Not Self-funding because of: debt over 4× operating profit.

What they sell

65% Innovative Medicine.

Innovative Medicine 65% · MedTech 35%

Where each dollar goes

Not available.

Cost lines aren't reported in a comparable form.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 163¢ of each $1 of profit.

Competitive advantage

Not measurable.

Returns on capital can't be computed from its filings (common for banks and insurers).

Future bets

16% on research.

$16.1B a year on R&D. $5.6B on equipment and buildings.

All figures from Johnson & Johnson's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.